This week, the House of Representatives passed a new bill that gives the FDA the power to require new warning labels on existing prescription drugs, and the power to request “post-approval” studies of medicines as warranted. It also gives the FDA the authority to levy fines as high as $10 million to companies that fail to comply. The bill passed with a 405-7 vote on Wednesday and is expected to be passed by the Senate and approved by the President.
U.S. companies are developing new safety measures in response to the continued rumbling of the Chinese Poison Train. The measures, along with renewed federal interest in food safety, suggest that we may be in the midst of a food safety revolution similar to the one that reformed the meatpacking industry after the publication of Upton Sinclaire’s “The Jungle.”
For the companies, the problem is two-fold: figuring out exactly what to test for and maintaining control over their network of suppliers, even as they turn to China for vast quantities of imports at lower prices.
Three companies are trying three different strategies to cope with the uncertain quality of China’s exports:
Honey can be labeled “pure” even if contains additives like high fructose corn syrup. Most people prefer the taste of 100% pure bee’s honey, but how can you test to be sure you are getting the good stuff? Testing the purity of honey is remarkably like testing the purity of a villager. To wit:
The USDA has vowed to safeguard your meat by fighting reckless meatpackers that want to test their dead cattle for mad cow disease. The USDA’s current policy of testing less than 1% of cows is clearly succeeding since none of you have caught Creutzfeldt-Jakob disease, the human variant of mad cow disease.
“There are serious problems here,” Cook [City Councilman] said Wednesday afternoon. “I think Lincoln customers deserve better. They are not getting what they have paid for.” The new guide has been beset with problems since its introduction. Complaints have ranged from the guide itself — ugly graphics, incomplete information, etc. — to problems with slow-reacting cable boxes and DVRs after the software was loaded into them, causing some subscribers to reboot one or more times a day.
- The development and testing of experimental blood substitutes has been fraught with controversy: Baxter International Inc. stopped research on one such product in 1998 when more than 20 patients given the substitute died.